The clinical efficacy of inductive chemotherapy with pemetrexed followed by radiotherapy for patients with lung adenocarcinoma
10.11904/j.issn.1002-3070.2015.02.004
- VernacularTitle:培美曲塞联合放射治疗中晚期肺腺癌的临床研究
- Author:
Jun LI
;
Xiangying XU
;
Jianyu XU
- Publication Type:Journal Article
- Keywords:
Lung;
Adenocarcinoma;
Radiotherapy;
Pemetrexed
- From:
Practical Oncology Journal
2015;(2):111-115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and toxicity of inductive chemotherapy with pemetrexed followed by radiotherapy for patients with lung adenocarcinoma .Methods Patients with stage Ⅲa/b or Ⅳ and histologically confirmed lung adenocarcinoma were evaluated from July 2008 to April 2012 ( n=95 ) .Patients re-ceived inductive chemotherapy with pemetrexed or paclitaxel followed by thoracic radiotherapy or chemotherapy with pemetrexed alone,respectively.Primary end point was the tumor response rate (RR),progression-free sur-vival(PFS),1-year survival rate and toxicity.Results Tumor RR were 83.3%,81.8%and 62.5% in three groups of inductive chemotherapy with pemetrexed or paclitaxel followed by thoracic radiotherapy or chemotherapy with pemetrexed alone ,respectively.PFS was 12.0 months,10.9 months and 5.7 months.The 1-year survival rate was 80.0%,78.7%and 46.8%.Tumor RR and PFS were statistically superior in pemetrexed/radiotherapy versus pemetrexed alone ,and toxicity was significantly lower than in paclitaxel /radiotherapy.Conclusion The treatment of pemetrexed/radiotherapy for lung adenocarcinoma could prolong the survival of patients .Compared with the treatment of paclitaxel/radiotherapy ,pemetrexed/radiotherapy provides similar efficacy with better tolera-bility and more convenient administration .
